Manic/hypomanic symptoms and quality of life measures in patients with epilepsy  by Mula, Marco et al.
Seizure 18 (2009) 530–532Manic/hypomanic symptoms and quality of life measures in patients
with epilepsy
Marco Mula a,*, Regina Jauch b, Andrea Cavanna a, Laura Collimedaglia a, Davide Barbagli a, Verena Gaus b,
Rebekka Kretz b, Michele Viana a, Roberto Cantello a, Francesco Monaco a, Bettina Schmitz b
a The Neuropsychiatry Research Group and the Epilepsy Centre, Department of Neurology, Amedeo Avogadro University, C.so Mazzini, 18, 28100 Novara, Italy
bUniversita¨tsmedizin-Charite´, Department of Neurology, Campus Virchow-Klinikum, Seizure Clinic, Berlin, Germany
A R T I C L E I N F O
Article history:
Received 23 January 2009
Accepted 15 May 2009
Keywords:
Epilepsy
Mania
Hypomania
Bipolar disorder
Quality of life
A B S T R A C T
Purpose: Although several studies pointed out an association between depression and quality of life
(QoL) of patients with epilepsy, data about manic/hypomanic symptoms (MHS) remain scanty. In this
study, we sought to investigate their relationship with social and health-related QoL measures in
patients with epilepsy.
Methods: Consecutive adult outpatients with epilepsy were assessed using theM.I.N.I. Plus version 5.0.0
and the QOLIE-31.
Results: Among 117 evaluated patients, 17 fulﬁlled DSM-IV criteria for manic/hypomanic episodes.
Patients with MHS, as compared to those without, showed lower scores in emotional well-being, energy
and fatigue, medication effects, social function and total QOLIE score. However, there was no between-
groups difference in educational achievements, employment status, living situation, comorbid
psychiatric disorders, history of suicide or abuse of illicit drugs.
Conclusions: MHS are associated with poor QoL measures in patients with epilepsy, though without
differences in educational achievements, employment status and independent living.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The impact and additional burden of psychiatric disorders in
patients with epilepsy, as in other chronic medical conditions, is
substantial, involving functioning,1 quality of life,2 health costs,
mortality3 and adherence to medical treatment.4 Behavioral
disorders often overshadow seizures and can be the greatest
cause of impaired quality of life.
It is widely accepted that mood disorders in epilepsy are often
undetected and undertreated, however, the majority of studies
focused on major depression with information about bipolar
disorder (BD) being still limited. In the older literature, it was often
stated that BD was rare in epilepsy.5 Such statements were made
prior to the use of standardized diagnostic manuals such as the
DSM-IV, andwere based upon clinical impressions rather than on a
systematic assessment with standardized interviews. It was
accepted, however, that affective symptoms, especially in the
context of a post-ictal state, might present with manic-like
features, although, more generally, the presentation is one of a
mixed affective state often with psychotic symptoms. Recent* Corresponding author. Tel.: +39 03213733371; fax: +39 03213733298.
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doi:10.1016/j.seizure.2009.05.008studies pointed out that manic or hypomanic post-ictal symptoms
are note rare in epilepsy and have distinguishing features.6–8
A large U.S. survey revealed that 12.2% of the epilepsy patients
screened positively for bipolar symptoms, which was twice as
common as in people with asthma, and seven times as common as
in the healthy comparison group. Of those who, in the screening
process, were rated as potential bipolar patients, nearly 50% were
rated by a physician as having a BD.8 These data raised some
doubts about previous suggestions that bipolarity is rare in people
with epilepsy, and raised doubts as to our knowledge of the
association between these two disorders. In a recent study, we
pointed out that bipolar symptoms frequently occur among
patients with epilepsy, although, in the majority of cases, these
symptoms are related to phenotype copies of BD, such as the
interictal dysphoric disorder, post-ictal manic or hypomanic states
and pre-ictal dysphoria.9 Nevertheless, it has to be acknowledged
that, althoughmanic/hypomanic symptoms (MHS) related to BD in
the strict sense differ considerably, all MHS need to be recognized
in studies of this area because the possible consequences can be
profound regardless the speciﬁc etiology, especially when the
duration and the severity of such symptoms are sufﬁcient to
warrant a diagnosis of manic episode according to DSM-IV criteria.
In fact, severe manic or mixed episodes, especially if psychotic
features are present, may have deleterious effects on socialvier Ltd. All rights reserved.
Table 1
Demographic and clinical variables in patients with epilepsy with and without
manic/hypomanic symptoms (MHS).
E-MHS (n = 17) E-noMHS (n = 100)
Gender (%)
Males 23.5 47.0
Females 76.5 53.0
Age, years (SD) 43.2 (12.2) 43.5 (14.8)
Age onset epilepsy, years (SD) 27.3 (20.2) 23.4 (18.6)
Epilepsy syndrome (%)
Partial 64.7 76
Generalized 29.4 24
NOS 5.9 0
TLE diagnosis (%) 66.7 66.3
EEG laterality (%)
Normal 37.5 29.5
Right 25.1 18.2
Left 18.8 22.7
Bilateral 12.5 15.9
Generalized 6.3 13.6
Normal MRI (%) 73.3 77.0
Seizure frequency (%)
Free 17.6 8.3
<10 year 23.5 31.3
1–10 month 41.2 52.1
11–20 month 5.9 4.2
>20 month 11.8 4.2
AEDs therapy regime (%)
Monotherapy 76.5 66.0
Dualtherapy 11.8 23.0
Polytherapy 11.8 8.0
Mood stabilizing AEDs
(CBZ, OXCBZ, VPA, LTG)
88.2 84
Table 2
Social and psychiatric variables in patients with epilepsy with and without manic/
hypomanic symptoms (MHS).
E-MHS
(n = 17)
E-noMHS
(n = 100)
Marital status (%)
Married or living with a partner 82.4 65.0
Not married or living alone 17.6 35.0
Educational achievements (%)
Achieved 46.7 70.1
Not achieved 53.3 29.9
Employment status (%)
Employed 41.2 53.1
Unemployed 52.9 31.6
Retired 5.9 15.3
Living status (%)
Independent 52.9 67.0
Dependent 47.1 33.0
Previous psychiatry history (%)
One diagnosis 29.4 19.4
Two or more 23.5 22.4
Lifetime DSM-IV diagnoses anxiety disorder (%) 47.1 36.0
Generalized anxiety disorder 5.9 13.0
Panic attack disorder 5.9 5.0
Social phobia 11.8 10.0
Agoraphobia without panic attacks 17.6 8.0
History of suicide (%) 5.9 5.1
Abuse of illicit drugs (%) 5.9 3.0
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regardless if they are post-ictal phenomena, part of an interictal
dysphoric disorder or due to a true manic-depressive illness.
Therefore, in this study, we sought to investigate the association
between MHS and social and health-related QOL measures in
patients with epilepsy.
2. Methods
Data were drawn from a collaborative study performed in
patients with epilepsy, aimed at investigating clinical and
psychopathological features of mood disorders in epilepsy.
Patients were recruited in two tertiary referral centers in Europe,
namely the Department of Neurology, Amedeo Avogadro Uni-
versity in Novara, Italy and the Department of Neurology,
Universita¨tsmedizin-Charite´, Berlin, Germany. To be enrolled,
patients had to fulﬁll the following criteria: (1) diagnosis of
epilepsy according to the ILAE criteria10; (2) age more than 18; (3)
absence of learning disabilities, a reading levelmore than 6th grade
and/or a MMSE > 24; (4) absence of severe medical illnesses or a
high risk of suicide; (5) be willing to provide a written informed
consent to undergo the experimental procedures.
Subjects were assessed using the Mini International Neurop-
sychiatric Interview (M.I.N.I.) Plus version 5.0.0, a validated DSM-
based structured interview for psychiatric disorders11 and the
Quality of Life in Epilepsy 31 Patient Inventory (QOLIE-31).12 The
M.I.N.I. Plus 5.0.0 was developed from the M.I.N.I.11 as an efﬁcient
diagnostic interview, to be used in clinical as well as research
settings, and follows DSM-IV and ICD-10 criteria, screening for a
number of Axis I diagnoses with brief suicidality and antisocial
personality modules. It has been validated in the United States and
Europe and is available in several languages. This standardized
interview was used to identify patients who presented MHS long
and severe enough to meet DSM-IV criteria for manic/hypomanic
episodes.
Demographic and social variables (age, gender, marital status,
educational achievements, employment status, independent liv-
ing), clinical features (age at onset and duration of the epilepsy,
seizure type and syndrome according to ILAE criteria, seizure
frequency, antiepileptic drug regime and combinations, MRI
features, EEG features and localization), psychopathological
characteristics (previous psychiatric history, history of suicide
attempts, history of abuse of illicit drugs) and health-related QOL
measures (total and subscales scores of QOLIE-31) were investi-
gated in patients with MHS as compared to those without. The
frequency of categorical variables was compared between-groups
using the x2 analysis or Fisher’s exact test. Continuous demo-
graphic and clinical variables were compared using the Mann-
Whitney test. The alpha error was set at 0.05. All statistical
analyses were 2-sided and conducted using the Statistical Package
for Social Sciences (Version 12 forWindows, SPSS Inc., Chicago, IL).
3. Results
Weanalyzed data of 117 patientswith epilepsy (51M, 66 F), age
(S.D.) 43.2 years (12.2), age of onset of epilepsy (S.D.) 27.3 years
(20.2). There was no between-groups difference in the two centers
(Berlin and Novara) in terms of age, gender, duration of the disease,
marital status, education level, employment, distribution of epilepsy
diagnoses, pattern and frequency of seizures.
A total of 17 patients (13 females) presented MHS that meet
DSM-IV criteria for manic/hypomanic episodes. Demographic and
social variables (age, gender, marital status, educational achieve-
ments, employment status, independent living) and clinical
features (age at onset of the epilepsy, epilepsy syndrome, seizure
type and frequency, MRI and EEG features or laterality) were notdifferent in these patients as compared to those without (Table 1).
Antiepileptic drug therapy was not different in the two groups; in
particular 42.7% were taking carbamazepine, 25.6% valproate,
17.9% lamotrigine, 15.4% levetiracetam, 10.3% barbiturates, 8.5%
Table 3
Mean total and subscales scores of QOLIE-31 in patients with epilepsy with and
without manic/hypomanic symptoms (MHS).
E-MHS
(n = 17)
E-noMHS
(n = 100)
Z-test P value
(2-tailed)
Seizure worry (S.D.) 47.0 (10.8) 49.9 (11.2) 1.06 0.292
Overall QOL (S.D.) 44.0 (11.8) 48.1 (10.4) 1.49 0.136
Emotional well-being (S.D.) 40.3 (10.4) 47.5 (9.7) 2.64 0.008
Energy and fatigue (S.D.) 42.5 (9.0) 48.2 (9.5) 2.05 0.039
Cognitive functioning (S.D.) 47.8 (11.3) 51.6 (10.2) 1.24 0.215
Medication effects (S.D.) 43.5 (9.3) 51.2 (9.0) 2.93 0.004
Social function (S.D.) 43.2 (10.7) 51.3 (10.0) 2.83 0.005
Total QOLIE score (S.D.) 42.2 (12.4) 49.8 (11.1) 2.21 0.026
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toin.
Previous psychiatric history, presence of lifetime comorbid
anxiety disorders, history of suicide attempts or abuse of illicit
drugs were not different in the two groups (Table 2). QOLIE-31
measures showed that patients with MHS have low scores in
emotional well-being (40.3  10.4 vs. 47.5  9.7, p = 0.008), energy
and fatigue (42.5  9.0 vs. 48.2  9.5, p = 0.039), medication effects
(43.5  9.3 vs. 51.2  9.0, p = 0.004), social function (43.2  10.7 vs.
51.3  10.0, p = 0.005) and total QOLIE score (42.2  12.4 vs.
49.8  11.1, p = 0.026) (Table 3).
4. Discussion
To the best of our knowledge, this is the ﬁrst study
demonstrating an association between MHS and social and
health-related QOL measures in patients with epilepsy, being
the majority of studies focused on depression and anxiety.13,14
Among different QoL domains, as assessed with the QOLIE-31,
associations with total QoL, emotional well-being, energy and
fatigue, and social function scores were expected. However, it is
interesting to note that social indicators of well-being such as
social achievements, independent living or the employment status
were not different in patients with MHS as well as the suicide rate
and the abuse of illicit drugs (Table 2). All these ﬁndings would be
in keepingwith the observation thatMHS in patients with epilepsy
might be attributed to clinical entities other than a true psychiatric
illness such as BD, and could be seizure-based phenomena (e.g.
pre-ictal dysphoria, peri-ictal excitement and so on).9 Never-
theless, it has also to be considered that a number of publications,
mainly in the psychiatric literature, are supporting the view that
depressive symptoms rather than MHS are the primary determi-
nants of QoL.15 Further studies on this issue are needed.
The observed association between MHS and ‘‘adverse effects’’
scores represents an interesting point deserving special attention
especially because not associated to low ‘‘cognitive functioning’’
scores (Table 3). A recent study pointed out that the subjective
perception of cognitive side effects of antiepileptic medications is
related more to depressive symptoms than the objective perfor-
mance.16 Our results suggest that, on the contrary, MHS may be
associated with other aspects such as worries about mental and
physical long term effects of drugs. This issue is of relevance
because such worries may considerably affect treatment com-
pliance. It is well known, from the psychiatric literature, that
bipolarity is associated with poor medication adherence, being
reported in half of patients due to dysfunctional thinking and
behavior references.17 Our results put forward the need of furtherresearch in this area to clarify whether patients with epilepsy and
MHS, independently from their origin, may require speciﬁc
psychosocial strategies and management approaches from profes-
sionals for antiepileptic drug adherence.
Limitations of our study should be noted. First, the small sample
size has limited the possibility of further analysis differentiating
between seizure-based MHS and true psychiatric symptoms.
Second, our results may not be representative for epilepsy patients
in general because our patients represent a highly selected sample
coming from tertiary referral centers.
5. Conclusions
In conclusion, MHS are associated with poor QoL measures in
patients with epilepsy, though without associations with educa-
tional achievements, employment status and independent living.
This may be in part due to the speciﬁc etiology ofMHS that seem to
be seizure-related behavioral manifestations. Further research in
unselected samples of patients with epilepsy differentiating
between true bipolar symptoms and seizure-based phenomena
are needed to estimate their association with QoL measures.
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